SunTrust Banks Comments on Epizyme Inc’s FY2022 Earnings (EPZM)

Epizyme Inc (NASDAQ:EPZM) – Equities research analysts at SunTrust Banks issued their FY2022 earnings estimates for shares of Epizyme in a report released on Tuesday. SunTrust Banks analyst P. Lawson anticipates that the biopharmaceutical company will post earnings per share of $2.32 for the year.

A number of other equities analysts have also commented on the stock. BidaskClub upgraded shares of Epizyme from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. ValuEngine upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Roth Capital began coverage on shares of Epizyme in a research report on Thursday, February 1st. They issued a “buy” rating and a $24.00 price target on the stock. Jefferies Group restated a “buy” rating and issued a $25.00 price target on shares of Epizyme in a research report on Wednesday, January 24th. Finally, Morgan Stanley assumed coverage on shares of Epizyme in a research report on Wednesday, January 10th. They issued an “overweight” rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $22.73.

Epizyme (NASDAQ:EPZM) traded up $0.50 during trading hours on Friday, reaching $17.60. 220,420 shares of the company’s stock were exchanged, compared to its average volume of 464,111. The firm has a market capitalization of $1,180.00, a price-to-earnings ratio of -7.60 and a beta of 2.19. Epizyme has a 52-week low of $9.30 and a 52-week high of $20.45.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas bought a new stake in shares of Epizyme during the fourth quarter worth approximately $202,000. Fox Run Management L.L.C. bought a new stake in shares of Epizyme during the third quarter worth approximately $223,000. Bailard Inc. bought a new stake in shares of Epizyme during the fourth quarter worth approximately $251,000. MetLife Investment Advisors LLC bought a new stake in shares of Epizyme during the fourth quarter worth approximately $263,000. Finally, JGP Global Gestao de Recursos Ltda. bought a new stake in shares of Epizyme during the third quarter worth approximately $292,000. 82.95% of the stock is owned by institutional investors and hedge funds.

In other news, COO Matthew Ros sold 72,264 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the transaction, the chief operating officer now directly owns 74,867 shares in the company, valued at $1,245,038.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 25.20% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/23/suntrust-banks-comments-on-epizyme-incs-fy2022-earnings-epzm.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply